ATE359079T1 - Verfahren zur behandlung von übelkeit, erbrechen, würgereiz oder jede kombination daraus - Google Patents

Verfahren zur behandlung von übelkeit, erbrechen, würgereiz oder jede kombination daraus

Info

Publication number
ATE359079T1
ATE359079T1 AT04701830T AT04701830T ATE359079T1 AT E359079 T1 ATE359079 T1 AT E359079T1 AT 04701830 T AT04701830 T AT 04701830T AT 04701830 T AT04701830 T AT 04701830T AT E359079 T1 ATE359079 T1 AT E359079T1
Authority
AT
Austria
Prior art keywords
vomiting
regaging
combination
treating nausea
nausea
Prior art date
Application number
AT04701830T
Other languages
English (en)
Inventor
Steven B Landau
Cheryl L Miller
Karl Bruce Thor
Original Assignee
Dynogen Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dynogen Pharmaceuticals Inc filed Critical Dynogen Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE359079T1 publication Critical patent/ATE359079T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Dental Preparations (AREA)
AT04701830T 2003-01-13 2004-01-13 Verfahren zur behandlung von übelkeit, erbrechen, würgereiz oder jede kombination daraus ATE359079T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44007603P 2003-01-13 2003-01-13
US49247803P 2003-08-04 2003-08-04

Publications (1)

Publication Number Publication Date
ATE359079T1 true ATE359079T1 (de) 2007-05-15

Family

ID=32718144

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04701830T ATE359079T1 (de) 2003-01-13 2004-01-13 Verfahren zur behandlung von übelkeit, erbrechen, würgereiz oder jede kombination daraus

Country Status (14)

Country Link
US (3) US20040147510A1 (de)
EP (1) EP1567163B1 (de)
JP (1) JP2006516977A (de)
KR (1) KR20050094843A (de)
AT (1) ATE359079T1 (de)
AU (1) AU2004204827B2 (de)
BR (1) BRPI0406748A (de)
CA (1) CA2512022A1 (de)
DE (1) DE602004005814T2 (de)
ES (1) ES2285407T3 (de)
MX (1) MXPA05007379A (de)
NZ (1) NZ541009A (de)
PL (1) PL378369A1 (de)
WO (1) WO2004062624A2 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0216027D0 (en) * 2002-07-10 2002-08-21 Arachnova Therapeutics Ltd New therapeutic use
US20040048874A1 (en) * 2001-05-22 2004-03-11 Bardsley Hazel Judith New therapeutic use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D]pyrimidine
AU2003259373B2 (en) * 2002-08-29 2006-03-09 Dynogen Pharmaceuticals, Inc. New therapeutic uses of (4-(2-Fluorophenyl)-6-methyl-2-(1-piperazinyl) thieno[2,3-D]pyrimidine
ES2285407T3 (es) * 2003-01-13 2007-11-16 Dynogen Pharmaceuticals Inc. Metodo para el tratamiento de nauseas, vomitos, arcadas o cualquiera de sus combinaciones.
KR20050111318A (ko) * 2003-01-13 2005-11-24 다이노젠 파마세우티컬스, 인코포레이티드 기능성 장 질환을 치료하는 방법
US8598219B2 (en) * 2003-01-30 2013-12-03 Helsinn Healthcare Sa Liquid pharmaceutical formulations of palonosetron
JO2735B1 (en) 2003-01-30 2013-09-15 هيلسين هيلث كير أس ايه. Liquid pharmaceutical formulations of palonosetron
CA2519379A1 (en) * 2003-04-04 2004-10-21 Dynogen Pharmaceuticals, Inc. Method of treating lower urinary tract disorders
WO2005007600A2 (en) * 2003-07-11 2005-01-27 Eisai Co., Ltd. Novel methods using aminobenzoic acid compounds
WO2005011583A2 (en) * 2003-07-28 2005-02-10 Leslie Joe Dunaway Treatment of allergic rhinitis and asthma
US20050282879A1 (en) * 2004-06-17 2005-12-22 Foad Salehani Methods and composition for treatment of migraine and symptoms thereof
CN101128432A (zh) * 2004-12-17 2008-02-20 詹森药业有限公司 用于治疗中枢神经系统疾病的四氢异喹啉化合物
WO2006105117A2 (en) * 2005-03-28 2006-10-05 Dynogen Pharmaceuticals, Inc. Method of treating disorders and conditions using peripherally-restricted antagonists and inhibitors
EP1906951A4 (de) * 2005-07-01 2009-05-27 Dynogen Pharmaceuticals Inc Zusammensetzungen und verfahren zur behandlung von gastrointestinaler hypomotilität und relevanter erkrankungen
US7776831B2 (en) * 2006-02-01 2010-08-17 Weg Stuart L Use of antifungal compositions to treat upper gastrointestinal conditions
US20070254899A1 (en) * 2006-03-31 2007-11-01 Dynogen Pharmaceuticals, Inc. Soluble salts of thieno[2,3-d]pyrimidine derivatives
US20070259933A1 (en) * 2006-05-04 2007-11-08 Xenoport, Inc. Compositions, dosage forms and methods of treating emesis
WO2008038106A1 (en) * 2006-09-27 2008-04-03 Orchid Chemicals & Pharmaceuticals Limited Venlafaxine extended release formulations
EP2432467B1 (de) * 2009-05-20 2018-02-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Serotonin-5-ht3-rezeptor-antagonisten zur verwendung bei der behandlung von vestibulären läsionsstörungen
MX378261B (es) 2013-03-14 2025-03-10 Redhill Biopharma Ltd Formas de dosificación sólidas de liberación prolongada antieméticas.
SG11201607511WA (en) * 2014-03-11 2016-10-28 Redhill Biopharma Ltd Ondansetron extended release solid dosage forms for treating either nausea, vomiting or diarrhea symptoms
HRP20240453T1 (hr) 2016-04-14 2024-06-21 Sensorion (+)-azasetron za uporabu u liječenju poremećaja uha
WO2022015628A2 (en) * 2020-07-15 2022-01-20 St. Jude Children's Research Hospital, Inc. Obese ferret model and methods of establishing and using the same
CA3217137A1 (en) 2021-04-29 2022-11-03 Christopher Adair Cannabidiol-dominant formulations, methods of manufacturing, and uses thereof
WO2023164132A1 (en) * 2022-02-25 2023-08-31 Neuraxis, Inc. Auricular nerve field stimulation device and methods for using the same

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US44450A (en) * 1864-09-27 Improvement in ore-crushers
US36549A (en) * 1862-09-23 Improvement in caps
US254171A (en) * 1882-02-28 Car-axle box
US254172A (en) * 1882-02-28 Half to laweence
US48874A (en) * 1865-07-18 Improved extension door-knobs
US107244A (en) * 1870-09-13 Improved manner of treating- cod-liver and castor-oils
US203055A (en) * 1878-04-30 Improvement in carpet-stretchers
US36500A (en) * 1862-09-23 Joseph banks
US4225407A (en) * 1979-04-04 1980-09-30 The Dow Chemical Company Cathodic electrodeposition of polymers onto a conductive surface
JPS60146891A (ja) * 1984-01-05 1985-08-02 Mitsubishi Chem Ind Ltd 〔２，３−ｄ〕チエノピリミジン誘導体およびその塩
EP0385517B1 (de) * 1985-03-14 1993-04-14 BEECHAM GROUP plc Arzneimittel zur Behandlung von Erbrechen
GB8516083D0 (en) * 1985-06-25 1985-07-31 Glaxo Group Ltd Heterocyclic compounds
GB8701022D0 (en) * 1987-01-19 1987-02-18 Beecham Group Plc Treatment
DE3885357T2 (de) * 1987-06-29 1994-03-24 Duphar Int Res Anellierte Indolderivate.
US5223511A (en) * 1987-09-23 1993-06-29 Boehringer Ingelheim Italia S.P.A. Benzimidazoline-2-oxo-1-carboxylic acid compounds useful as 5-HT receptor antagonists
CA1304082C (en) 1987-10-22 1992-06-23 Tetsuya Tahara Benzoxazine compounds and pharmaceutical use thereof
US5530008A (en) * 1989-04-21 1996-06-25 Sandoz Ltd. Use of 5-HT3 receptor antagonists in treating panic disorders or obsessive compulsive disorders
US5225407A (en) * 1990-02-22 1993-07-06 Glaxo Group Limited 5-HT3 receptor antagonists for the treatment of autism
WO1993000074A1 (en) * 1991-06-26 1993-01-07 Sepracor, Inc. Method and compositions for treating emesis, nausea and other disorders using optically pure r(+) ondansetron
JP2699794B2 (ja) * 1992-03-12 1998-01-19 三菱化学株式会社 チエノ〔３，２−ｂ〕ピリジン誘導体
GB9214184D0 (en) 1992-07-03 1992-08-12 Smithkline Beecham Plc Pharmaceuticals
JPH0616557A (ja) * 1992-12-21 1994-01-25 Mitsubishi Kasei Corp 脳機能障害改善剤
GB9406857D0 (en) * 1994-04-07 1994-06-01 Sandoz Ltd Improvements in or relating to organic compounds
US5576317A (en) * 1994-12-09 1996-11-19 Pfizer Inc. NK-1 receptor antagonists and 5HT3 receptor antagonists for the treatment of emesis
DK0855397T3 (da) * 1995-07-28 2001-06-25 Dainippon Pharmaceutical Co (R)-5-brom-N-(ethyl-4-methylhexahydro-1H-1,4-diazepin-6-yl)-2-methoxy-6-methylamino-3-pyridincarboxamid, fremgangsmåde til dets fremstilling og medicinsk præparat indeholdende denne forbindelse
AU702594B2 (en) * 1995-10-13 1999-02-25 Duphar International Research B.V. Process for the preparation of enantiomerically pure imidazolyl compounds
JP2000516198A (ja) * 1996-02-15 2000-12-05 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ セロトニンの再取り込み阻害剤の胃腸に対する作用を克服するための５ｈｔ４レセプター拮抗剤の使用
AU745361B2 (en) * 1997-04-18 2002-03-21 Janssen Pharmaceutica N.V. Use of 5HT3 antagonists for promoting intestinal lavage
JPH10298078A (ja) 1997-05-06 1998-11-10 Mitsubishi Chem Corp 抗不安薬
ES2128266B1 (es) 1997-07-08 2000-01-16 Vita Invest Sa Compuestos derivados de tiofeno y benzotiofeno y utilizacion y composicion correspondientes.
DE19813661A1 (de) * 1997-08-01 1999-02-04 Solvay Pharm Gmbh Gegen Racemisierung stabilisierte pharmazeutische Zubereitungen von Cilansetron
DE19734444A1 (de) * 1997-08-08 1999-02-11 Basf Ag 3-Substituierte 3,4,5,7-Tetrahydro-pyrrolo(3',4':4,5) thieno (2,3-d) pyrimidin-Derivate, ihre Herstellung und Verwendung
US6156771A (en) * 1997-08-28 2000-12-05 Rubin; Walter Method for alleviation of lower gastrointestinal disorders in a human patient
US6117879A (en) * 1997-09-16 2000-09-12 Solvay Pharmaceuticals Gmbh Methods of using moxonidine to inhibit nociceptive pain
US6054461A (en) * 1997-09-16 2000-04-25 Solvay Pharmaceuticals Gmbh Treatment of neuropathic pain
GB9721139D0 (en) * 1997-10-07 1997-12-03 Glaxo Group Ltd Medicaments
FR2781671A1 (fr) 1998-07-28 2000-02-04 Synthelabo Compositions pharmaceutiques contenant un inhibiteur de la recapture de la serotonine et leur application en therapeutique
US6376550B1 (en) * 1999-02-09 2002-04-23 Asta Medica Ag Pharmaceutical compositions containing tramadol for migraine
WO2000048581A2 (en) * 1999-02-18 2000-08-24 Novartis Ag Use of 5-ht3 receptor antagonists for treating musculoeskeletal diseases
US6362202B1 (en) * 1999-03-02 2002-03-26 Sepracor Inc. Methods and compositions using (−) norcisapride in combination with proton pump inhibitors or H2 receptor antagonists
US6353005B1 (en) * 1999-03-02 2002-03-05 Sepracor, Inc. Method and compositions using (+) norcisapride in combination with proton pump inhibitors or H2 receptor antagonist
GB2355932B (en) * 1999-04-12 2004-01-07 Univ Madras A pharmaceutical formulation suitable for the treatment of hepatitis B, hepatitis C and other viral infections of the liver and a process for its preparation
DE19929197A1 (de) * 1999-06-25 2000-12-28 Novosis Pharma Ag Transdermalsysteme zur Abgabe von 5-HT3-Rezeptor-Antagonisten und ihre Verwendung zur antiemitischen Behandlung
ATE305788T1 (de) * 1999-07-01 2005-10-15 Pharmacia & Upjohn Co Llc (s,s)-reboxetin zur behandlung von inkontinenz
GB2355191A (en) * 1999-10-12 2001-04-18 Laxdale Ltd Combination formulations for fatigue, head injury and strokes
TWI263496B (en) 1999-12-10 2006-10-11 Novartis Ag Pharmaceutical combinations and their use in treating gastrointestinal disorders
ES2188344B1 (es) 2000-11-29 2004-09-16 Laboratorios Vita, S.A. Compuestos derivados de benzotiofeno, su procedimiento de obtencion y utilizacion de los mismos.
US20020107244A1 (en) * 2001-02-02 2002-08-08 Howard Harry R. Combination treatment for depression
US20040048874A1 (en) * 2001-05-22 2004-03-11 Bardsley Hazel Judith New therapeutic use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D]pyrimidine
GB0112494D0 (en) 2001-05-22 2001-07-11 Arachnova Therapeutics Ltd New therapeutic use
GB0216027D0 (en) * 2002-07-10 2002-08-21 Arachnova Therapeutics Ltd New therapeutic use
AU2003210610B2 (en) * 2002-01-18 2007-11-29 Aryx Therapeutics 5-HT3 receptor antagonists and methods of use
GB0202265D0 (en) * 2002-01-31 2002-03-20 Arachnova Therapeutics Ltd New therapeutic use
PT1485078E (pt) * 2002-03-15 2013-01-14 Cypress Bioscience Inc Milnacipran para o tratamento do síndrome do intestino irritável
CN1668307A (zh) 2002-07-10 2005-09-14 阿瑞科诺沃治疗有限公司 治疗功能性肠紊乱的4－(2－氟苯基)－6－甲基－2－(1－哌嗪基)噻吩并[2,3－d]嘧啶
AU2003259373B2 (en) * 2002-08-29 2006-03-09 Dynogen Pharmaceuticals, Inc. New therapeutic uses of (4-(2-Fluorophenyl)-6-methyl-2-(1-piperazinyl) thieno[2,3-D]pyrimidine
WO2004058353A2 (en) 2002-12-24 2004-07-15 Paradigm Therapeutics Ltd. Therapeutic use of selective noradrenaline reuptake inhibitors
ES2285407T3 (es) * 2003-01-13 2007-11-16 Dynogen Pharmaceuticals Inc. Metodo para el tratamiento de nauseas, vomitos, arcadas o cualquiera de sus combinaciones.
KR20050111318A (ko) * 2003-01-13 2005-11-24 다이노젠 파마세우티컬스, 인코포레이티드 기능성 장 질환을 치료하는 방법

Also Published As

Publication number Publication date
AU2004204827B2 (en) 2006-06-29
EP1567163A2 (de) 2005-08-31
US20040147510A1 (en) 2004-07-29
JP2006516977A (ja) 2006-07-13
MXPA05007379A (es) 2006-02-10
WO2004062624A2 (en) 2004-07-29
EP1567163B1 (de) 2007-04-11
US20040254172A1 (en) 2004-12-16
US7094786B2 (en) 2006-08-22
NZ541009A (en) 2007-09-28
DE602004005814T2 (de) 2008-01-10
BRPI0406748A (pt) 2005-12-20
EP1567163A4 (de) 2006-01-18
ES2285407T3 (es) 2007-11-16
US20040254171A1 (en) 2004-12-16
WO2004062624A3 (en) 2005-04-07
CA2512022A1 (en) 2004-07-29
AU2004204827A1 (en) 2004-07-29
DE602004005814D1 (de) 2007-05-24
KR20050094843A (ko) 2005-09-28
PL378369A1 (pl) 2006-04-03

Similar Documents

Publication Publication Date Title
DE602004005814D1 (de) Verfahren zur behandlung von übelkeit, erbrechen, würgereiz oder jede kombination daraus
AP2006003621A0 (en) Methods for treatment modification and management of pains using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoin-doleline
IL144643A0 (en) Jak-3 inhibitors for treating allergic disorders
DE60037394D1 (de) VERWENDUNG VON p53 INHIBITOREN ZUR BEHANDLUNG VON NEBENERSCHEINUNGEN BEI DER KREBSTHERAPIE
MY151032A (en) Treatment of tnf? related disorders
CY1107640T1 (el) Μεθοδος για πιστοποιηση παραγοντων για τη θεραπεια διαβητη
PL1654253T3 (pl) Podstawione pochodne 3-pirolidynoindolu
DE60321929D1 (de) Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen
DE60136826D1 (de) Verwendung von asiatsäure oder asiaticosid zur behandlung von krebs
DE602004008304D1 (de) Pteridin-derivate zur behandlung von erkrankungen im zusammenhang mit tnf-alpha
IS6925A (is) Aðferð og skömmtunarform til meðhöndlunar æxla með gjöf tegafúrs, úracíls, fólínsýru, paclítaxels og karbóplatíns
SG153661A1 (en) Formulation and methods for the treatment of thrombocythemia
DE50114605D1 (de) No-thien-2-yl-essigsaure-derivate und ihre verwendung zur behandlung von migraine bzw. schmerz
TR200200278T2 (tr) Kalsilitik bileşimler
ATE359808T1 (de) Verwendung von sarp-1 zur behandlung und/oder vorbeugung von scleroderma
DE50100833D1 (de) Verwendung von 2-methyl-thiazolidin-2,4-dicarbonsäure und / oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen
CY1108980T1 (el) Χρηση πολυσουλφωμενων κυκλοδεξτρινων για τη θεραπεια της αρθριτιδας
DE60112768D1 (de) Behandlung von entzündlichen erkrankungen
BR0312511A (pt) 4- (2-fluorofenil)-6-metil-2- (1-piperazinil) tieno [2,3-d] pirimidina no tratamento de distúrbio funcional dos intestinos
ATE314066T1 (de) Verwendung von buprenorphin zur therapie der harninkontinenz
ATE460168T1 (de) Nicht-radioaktives strontiummittel zur behandlung von krebs
DE60219616D1 (de) Verwendung von 4-(2-Fluorophenyl)-6-Methyl-2-(1-Piperazinyl) Thieno (2,3-D)Pyrimidin zur Schmerzbehandlung
GB0216027D0 (en) New therapeutic use
PL375354A1 (en) Use of treosulfan and derivatives thereof for treating multiple sclerosis
WO2004026102A3 (en) Treatment of schizophrenia

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties